6533b85bfe1ef96bd12ba1f9
RESEARCH PRODUCT
Glucose and Erythrocyte ATP: Distinctive Effects of Dipyridamole and of Ticlopidine
E. SchramR. SneppeJ.v. FenollarM. CloarecM. KahnH. SolvayS. Garreynsubject
Blood Glucosemedicine.medical_specialtyAdenosineErythrocytesTiclopidineArteriosclerosismedicine.medical_treatmentEconomic shortage030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundAdenosine Triphosphate0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineTiclopidineChemotherapyPlasma glucosebusiness.industryDipyridamoleAdenosineDipyridamoleRed blood cellEndocrinologymedicine.anatomical_structurechemistryDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessAdenosine triphosphatemedicine.drugdescription
This experiment suggests the following points: 1. Erythrocytes in control patients and in atherosclerosis patients seem to have a variable grade of affinity for adenosine and for plasma glucose. This variable grade seems to fix the level of the adenosine triphosphate (ATP) reserves and induces the erythrocytes' deformability. 2. The drop in the level of ATP reserves that induces the poor deformability of the erythrocytes in atherosclerosis patients would appear to be caused by two consecutive shortages: first a shortage that seems to be related to a deficiency of erythrocyte adenosine as the ATP shortage disappears with dipyridamole treatment and then a shortage induced by the lack of erythrocyte glucose and suppressed by the addition of ticlopidine to the dipyridamole treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1987-11-01 | Angiology |